Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Refractory Inflammatory Myopathies and Myasthenia Gravis
NCT00774462Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2008
- Primary completion
- Dec 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in inflammatory myopathy (IIM), myasthenia gravis (MG), sponsored by Assistance publique - Hôpitaux de Paris. Started Jan 2008; status: completed.
02
Drugs
rituximab
03
Conditions
inflammatory myopathy (IIM)myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT00774462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00774462.